Advances in clinical chemistry. Volume 109 /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Makowski, Gregory S. (Gregory Stephen) (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam : Academic Press, 2022.
Colección:ISSN
Temas:
Clinical chemistry.
Chemistry, Clinical
Chimie clinique.
Clinical chemistry
Acceso en línea:Texto completo
Tabla de Contenidos:
  • 6. Summary and future perspectives
  • Author contributions
  • Conflicts of interest
  • References
  • Chapter Four: Oligoclonal bands: An immunological and clinical approach
  • 1. Introduction
  • 2. Evolution in the techniques and detection methods of IgG OCBs
  • 2.1. Electrophoresis (EP) on agarose gel
  • 2.2. Isoelectric focusing (IEF) technique
  • 2.3. Sensitivity and specificity of the immunodetection methods based on EP on agarose gel and IEF
  • 2.4. Commercial kits for detection of IgG OCBs
  • 3. Determination of IgG OCBs within the diagnostic criteria of MS: An overview
  • 4. IEF as reference technique in IgG OCBs detection
  • 5. A single band of IgG immunoglobulin in CSF
  • 6. Prevalence of IgG OCBs and effect of latitude in MS
  • 7. OCBs of IgM isotype: An overview
  • 7.1. Introduction
  • 7.2. Evolution in the techniques and detection methods
  • 7.3. Clinical and immunological significance of IgM OCBs
  • 8. Clinical usefulness of IgG OCBs in neurological diseases
  • 9. Summary and future perspectives
  • References
  • Chapter Five: Immunoassay design and biotin interference
  • 1. Introduction
  • 2. Biotin: Overview of pharmacology
  • 3. Biotin supplements
  • 4. Serum biotin
  • 5. Biotin based immunoassays and biotin interference
  • 6. Clinically significant interferences due to elevated biotin concentrations
  • 7. Biotin interference in thyroid testing
  • 8. Biotin interference in PTH testing
  • 9. Biotin interference in troponin testing
  • 10. FDA communication on biotin
  • 11. Biotin interference in multiple immunoassays
  • 12. Threshold biotin concentration for interference
  • 13. Prevalence of clinically significant biotin interference
  • 14. Mitigation of biotin interference
  • 15. Conclusions
  • References
  • Chapter Six: Orexin/hypocretin and major psychiatric disorders
  • 1. Introduction
  • 2. Orexin and narcolepsy
  • 3. Schizophrenia.
  • 3.1. Clinical studies
  • 3.2. Antipsychotics
  • 3.2.1. Animal studies
  • 3.2.2. Clinical studies
  • 3.3. Psychotic polydipsia
  • 3.3.1. Animal studies
  • 3.3.2. Clinical studies
  • 4. Major Depressive Disorder (MDD)
  • 4.1. Animal studies
  • 4.1.1. Genetic
  • 4.1.2. Early life stress (ELS)
  • 4.1.3. Treatment during adulthood
  • 4.1.3.1. Social defeat model
  • 4.1.3.2. Unpredictable chronic mild stress (UCMS)
  • 4.1.3.3. Orexin injection
  • 4.1.3.4. Other models
  • 4.1.4. Animal studies on Orexin receptors
  • 4.2. Clinical studies
  • 4.3. Medications
  • 5. Bipolar disroder
  • 6. Other studies
  • 7. Conclusion
  • Acknowledgment
  • References
  • Index.

Ejemplares similares